China biotech start-up Lianbio files for US IPO LianBio, a two-year-old Chinese biotech start-up incubated by life sciences investor Perceptive Advisors, has filed for a US IPO. The three largest institutional investors are Perceptive with 62.4%, RA Capital with 7.2%, and BridgeBio Pharma with 5.8%, according to the prospectus. US-based BridgeBio is also a strategic partner, giving... Latest News [China Renaissance hits first close on flagship US dollar fund] Huaxing Growth Capital, a new economy-focused private equity division of China Renaissance, has reached the first close on its fourth US dollar-denominated fund of $550 million. [East, Vulcan lead $15m Series...